Ciprofloxacin

Generic Name: Ciprofloxacin

Brand Names: Cetraxal, Ciloxan, Cipro, Cipro HC, Ciprodex, Ciprofloxacin, Otiprio, Otixal, Otovel, Proquin

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈FN_₃O_₃

CAS Number: 85721-33-1

Unique Ingredient Identifier: 5E8K9I0O4U

Background: Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.

The first ciprofloxacin containing product was FDA approved on 22 October 1987.

Indication: Ciprofloxacin is only indicated in infections caused by susceptible bacteria.
...

Associated Conditions: Acute Exacerbations of Chronic Bronchitis caused by Moraxella catarrhalis, Acute Otitis Externa, Acute Otitis Externa caused by Pseudomonas Aeruginosa, Acute Otitis Media (AOM), Acute Sinusitis, Acute Uncomplicated Pyelonephritis, Bone and Joint Infections, Chronic Otitis Media, Complicated Intra-Abdominal Infections (cIAIs), Complicated Urinary Tract Infection, Conjunctivitis caused by Haemophilus influenzae, Conjunctivitis caused by Staphylococcus epidermidis, Corneal Ulcers caused by Serratia marcescens, Corneal Ulcers caused by Staphylococcus aureus, Corneal Ulcers caused by Staphylococcus epidermidis, Corneal Ulcers caused by Streptococcus Pneumoniae, Corneal Ulcers caused by Streptococcus Viridans Group, Corneal Ulcers caused by pseudomonas aeruginosa, Escherichia urinary tract infection, External ear infection NOS, Febrile Neutropenia, Infection of the outer ear caused by susceptible bacteria, Infectious diarrhea, Inhalational Anthrax, Lower respiratory tract infection caused by Enterobacter cloacae, Lower respiratory tract infection caused by Escherichia coli, Lower respiratory tract infection caused by Haemophilus influenzae, Lower respiratory tract infection caused by Haemophilus parainfluenzae, Lower respiratory tract infection caused by Klebsiella pneumoniae, Lower respiratory tract infection caused by Proteus mirabilis, Lower respiratory tract infection caused by penicillin-susceptible Streptococcus pneumoniae, Nosocomial Pneumonia, Otitis Media (OM), Otitis Media, Purulent, Plague caused by Yersinia pestis, Skin Infections, Typhoid fever caused by Salmonella typhi, UTI caused by Citrobacter diversus, UTI caused by Citrobacter frendii, UTI caused by Entercococcus faecalis, UTI caused by Enterobacter cloacae, UTI caused by Klebsiella pneumoniae, UTI caused by Morganella morganii, UTI caused by Proteus mirabilis, UTI caused by Providencia rettgeri, UTI caused by Pseudomonas aeruginosa, UTI caused by Serratia marcescens, UTI caused by methicillin-susceptible Staphylococcus epidermidis, Uncomplicated Urinary Tract Infections, Acute otitis externa caused by Staphylococcus aureus, Acute, uncomplicated Cystitis caused by Escherichia coli, Acute, uncomplicated Cystitis caused by Staphylococcus saprophyticus, Chronic Prostatitis caused by Escherichia coli, Chronic Prostatitis caused by Proteus mirabilis, Complicated Pyelonephritis caused by Escherichia coli, Complicated Urinary Tract Infection caused by Escherichia Coli, Uncomplicated Gonorrhea caused by Neisseria gonorrhoeae

Associated Therapies: -

Clinical Trials

S. Aureus Decolonization in HPN Patients.

Not Applicable

Terminated

Conditions: Motility Disorder
Staphylococcus Aureus

Interventions: Drug: Doxycycline
Drug: Trimethoprim
Drug: Sulfamethoxazole/trimethoprim
Drug: Clindamycin
Drug: Clarithromycin
Drug: Ciprofloxacin
Drug: Fusidic Acid
Drug: Rifampin
Drug: Chlorhexidine
Drug: Mupirocin
Drug: Betadine

First Posted Date: 2017-06-01

Last Posted Date: 2022-05-31

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 63

Registration Number: NCT03173053

Locations: 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇩🇰
Aalborg Universitetshospital, Aalborg, Denmark
🇳🇱
Radboud UMC, Nijmegen, Gelderland, Netherlands

and more 1 locations

Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis

Phase 4

Conditions: Critical Illness
Mechanical Ventilation Complication

Interventions: Drug: placebo
Drug: ceftriaxone
Drug: ciprofloxacin
Drug: imipenem
Drug: linezolid

First Posted Date: 2017-01-06

Last Posted Date: 2022-08-17

Lead Sponsor: University Hospital, Lille

Target Recruit Count: 154

Registration Number: NCT03012360

Locations: 🇫🇷
Hôpital Roger Salengro, CHRU, Lille, France

Clinical Validation of a Molecular Test for Ciprofloxacin-Susceptibility in Neisseria Gonorrhoeae

Not Applicable

Completed

Conditions: Gonococcal Infection

Interventions: Drug: Ciprofloxacin

First Posted Date: 2016-11-11

Last Posted Date: 2020-08-25

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 211

Registration Number: NCT02961751

Locations: 🇺🇸
Los Angeles Lesbian Gay Bisexual/Transgender Center, Los Angeles, California, United States
🇺🇸
University of California, San Diego Health - Owen Clinic, San Diego, California, United States
🇺🇸
AIDS Healthcare Foundation Wellness Center - Hollywood, Los Angeles, California, United States

and more 6 locations

Antibiotic Prophylaxis With Routine Ureteral Stent Removal

Not Applicable

Recruiting

Conditions: Urolithiasis
UTI

Interventions: Drug: No Intervention
Drug: Ciprofloxacin
Drug: trimethoprim/sulfamethoxazole

First Posted Date: 2016-10-26

Last Posted Date: 2020-03-24

Lead Sponsor: University of California, San Diego

Target Recruit Count: 80

Registration Number: NCT02944825

Locations: 🇺🇸
University of California, San Diego, San Diego, California, United States

Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia

Phase 4

Completed

Conditions: Early Stage Breast Cancer

Interventions: Drug: Ciprofloxacin
Drug: Neupogen

First Posted Date: 2016-06-28

Last Posted Date: 2020-05-27

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 458

Registration Number: NCT02816112

Locations: 🇨🇦
The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis

Phase 4

Completed

Conditions: Pouchitis

Interventions: Drug: Vedolizumab Placebo
Drug: Vedolizumab
Drug: Ciprofloxacin

First Posted Date: 2016-06-03

Last Posted Date: 2022-02-24

Lead Sponsor: Takeda

Target Recruit Count: 102

Registration Number: NCT02790138

Locations: 🇧🇪
UZ Leuven - University Hospital Gasthuisberg, Leuven, Belgium
🇳🇱
Academic Medical Center, Amsterdam, Netherlands
🇮🇹
Azienda Ospedaliera S. Orsola-Malpighi, Bologna, Italy

and more 31 locations

Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease

Phase 2

Completed

Conditions: Crohn's Disease

Interventions: Drug: Fluconazole
Drug: Vancomycin
Drug: Neomycin
Drug: Ciprofloxacin
Drug: Polyethylene Glycol 3350
Drug: Fluconazole placebo
Drug: Promethazine

First Posted Date: 2016-05-06

Last Posted Date: 2024-02-06

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 8

Registration Number: NCT02765256

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Antibiotic Prophylaxis for Transrectal Prostate Biopsy-Ciprofloxacin vs. Trimethoprim/Sulfamethoxazole

Phase 2

Conditions: Prostate Infection

Interventions: Drug: Trimethoprim/Sulfamethoxazole
Drug: Ciprofloxacin

First Posted Date: 2016-04-12

Last Posted Date: 2019-05-15

Lead Sponsor: Umeå University

Target Recruit Count: 2800

Registration Number: NCT02734732

Locations: 🇸🇪
Östersunds hospital, Östersund, Jämtland, Sweden
🇸🇪
Sundsvalls hospital, Sundsvall, Västernorrland, Sweden
🇸🇪
Umea University Hospital, Umea, Sweden

and more 2 locations